InflaRx N.V. (IFRX)
0.89
-0.04 (-4.19%)
At close: Apr 10, 2025, 3:59 PM
0.91
2.74%
After-hours: Apr 10, 2025, 07:59 PM EDT
-4.19% (1D)
| Bid | 0.89 |
| Market Cap | 59.75M |
| Revenue (ttm) | 166K |
| Net Income (ttm) | -46.12M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -2.07 |
| Analyst | Strong Buy |
| Ask | 0.91 |
| Volume | 416,465 |
| Avg. Volume (20D) | 403,360 |
| Open | 0.95 |
| Previous Close | 0.93 |
| Day's Range | 0.86 - 1.02 |
| 52-Week Range | 0.82 - 2.81 |
| Beta | 2.22 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III c...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2017
Employees 74
Stock Exchange NASDAQ
Ticker Symbol IFRX
Website https://www.inflarx.de
Analyst Forecast
According to 2 analyst ratings, the average rating for IFRX stock is "Strong Buy." The 12-month stock price forecast is $9, which is an increase of 911.24% from the latest price.
Stock ForecastsNext Earnings Release
InflaRx N.V. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-25.93%
InflaRx shares are trading lower after the company...
Unlock content with
Pro Subscription
1 month ago
+5.06%
InflaRx shares are trading lower after the company announced a public offering, the size or amount not disclosed.
